India Proposes New Body With GM-Based Drug Authority
This article was originally published in PharmAsia News
India's National Biotechnology Regulatory Authority now in the planning stage may be given responsibility for genetically modified drugs, taking them away from the Drug Controller General of India. The DCGI has responsibility for recombinant biologics, DNA vaccines and other GM drugs from the clinical stage to the market. Draft legislation, however, would transfer that purview to the proposed NBRA, whose role would be confined to drugs such as live vaccines containing organisms, but not human insulin or recombinant vaccines derived from, but not containing GMOs. (Click here for more
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.